About True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway and committed to rare diseases of high unmet clinical need, like autoimmune hemolytic anemia. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway and is now in clinical trials.